Brokerages Set Hikma Pharmaceuticals PLC (LON:HIK) Target Price at GBX 1,687

Hikma Pharmaceuticals PLC (LON:HIK) has earned a consensus rating of “Buy” from the six ratings firms that are covering the stock, MarketBeat Ratings reports. Six analysts have rated the stock with a buy rating. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is GBX 1,687.

A number of analysts have issued reports on HIK shares. Jefferies Financial Group raised their target price on Hikma Pharmaceuticals from GBX 1,850 to GBX 1,870 and gave the company a “buy” rating in a report on Tuesday, May 5th. Berenberg Bank reissued a “buy” rating and issued a GBX 1,800 target price on shares of Hikma Pharmaceuticals in a report on Tuesday, April 28th. Citigroup restated a “buy” rating on shares of Hikma Pharmaceuticals in a research report on Thursday, July 16th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a GBX 195 price target on shares of Hikma Pharmaceuticals in a research note on Monday, June 22nd.

Hikma Pharmaceuticals Stock Performance

HIK stock opened at GBX 1,567 on Thursday. The company has a quick ratio of 1.27, a current ratio of 1.82 and a debt-to-equity ratio of 61.84. The company has a market capitalization of £3.30 billion, a price-to-earnings ratio of 8.66, a P/E/G ratio of 2.38 and a beta of 0.65. Hikma Pharmaceuticals has a 12 month low of GBX 1,187 and a 12 month high of GBX 2,046. The firm has a 50 day moving average of GBX 1,500.26 and a two-hundred day moving average of GBX 1,448.51.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.